Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Achv save search
Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)
Published: 2023-07-11 (Crawled : 15:00) - globenewswire.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 1.56%
H: 6.54%
C: 0.77%
life association publication sciences medical trial
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
Published: 2023-05-23 (Crawled : 10:00) - globenewswire.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: -4.29%
H: 0.0%
C: -20.38%
life sciences trial
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
Published: 2023-04-20 (Crawled : 14:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 4.42%
H: 1.09%
C: -7.1%
life positive sciences trial results
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking CessationTopline Data Expected in 2Q 2023
Published: 2023-03-29 (Crawled : 15:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 0.9%
H: 8.04%
C: 6.61%
life expected sciences trial
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette CessationTopline Data Expected in 2Q 2023
Published: 2023-03-08 (Crawled : 18:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: -0.59%
H: 2.38%
C: 1.79%
sciences life expected trial
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Published: 2023-03-08 (Crawled : 13:00) - globenewswire.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: -0.59%
H: 2.38%
C: 1.79%
sciences life trial
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
Published: 2023-03-03 (Crawled : 13:00) - globenewswire.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 0.0%
H: 9.05%
C: 7.79%
sciences research meeting life trial presentation
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette CessationTopline Data Expected in 2Q 2023
Published: 2023-02-07 (Crawled : 14:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 0.0%
H: 3.46%
C: 3.46%
sciences life expected trial
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Published: 2023-01-09 (Crawled : 18:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 0.77%
H: 7.03%
C: 6.46%
sciences life trial
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial
Published: 2022-09-27 (Crawled : 13:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 1.65%
H: 1.89%
C: -8.92%
trial
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
Published: 2022-06-29 (Crawled : 13:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: -2.9%
H: 1.99%
C: 1.0%
sciences life trial phase 2
Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers
Published: 2022-04-27 (Crawled : 13:20) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: -2.43%
H: 8.03%
C: 2.91%
trial results phase 3
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Published: 2022-01-25 (Crawled : 13:30) - achievelifesciences.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: -0.99%
H: 4.56%
C: 1.78%
trial life science phase 3
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking CessationTopline ORCA-2 Results Expected in Q2 2022
Published: 2022-01-04 (Crawled : 15:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
trial results topline life science phase 3
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
Published: 2022-01-04 (Crawled : 14:00) - achievelifesciences.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
trial life science phase 3
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
Published: 2021-11-22 (Crawled : 13:30) - achievelifesciences.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
life science phase 3 trial
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
Published: 2021-06-29 (Crawled : 11:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: -3.3%
phase 3 trial enroll
A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial)
Published: 2021-04-14 (Crawled : 01:00) - achievelifesciences.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: -3.81%
H: 5.35%
C: 1.39%
phase 2 phase 2b trial
Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research
Published: 2021-04-14 (Crawled : 11:00) - biospace.com/
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 1.03%
H: 4.99%
C: -3.14%
phase 2 phase 2b research trial
Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) in Addiction
Published: 2021-03-25 (Crawled : 13:00) - achievelifesciences.com
ACHV | $4.51 -1.31% -1.33% 35K
|
Health Technology
|
| O: 0.76%
H: 3.36%
C: 0.59%
trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.